title: Profile of darunavir in the management of treatment-experienced HIV patients.
abstract: Darunavir (formerly TMC114) is a second-generation, sulfonamide-based, peptidomimetic protease inhibitor (PI) with a modified 3-dimensional structure enabling more efficient binding to HIV protease. It has become an important drug, in combination with low-dose ritonavir boosting, in the treatment of both antiretroviral-naïve and multiclass-experienced patients. Growing data now exist suggesting it possesses a high barrier to resistance and requires multiple PI mutations in order to suffer reduced virological potency.
authors.affiliation: Duke University Medical Center, Division of Infectious Diseases, Durham, NC, USA.
authors.forename: Cameron
authors.initials: C
authors.lastname: Wolfe
authors.forename: Charles
authors.initials: C
authors.lastname: Hicks
references.citation: J Clin Pharmacol. 2007 Apr;47(4):479-84
references.pmid: 17389557
references.citation: AIDS Res Hum Retroviruses. 2008 Mar;24(3):379-88
references.pmid: 18327986
references.citation: AIDS. 2008 Jul 31;22(12):1389-97
references.pmid: 18614861
references.citation: Antimicrob Agents Chemother. 2003 Oct;47(10):3123-9
references.pmid: 14506019
references.citation: AIDS. 2007 May 31;21(9):1210-3
references.pmid: 17502734
references.citation: Antimicrob Agents Chemother. 2005 Jun;49(6):2314-21
references.pmid: 15917527
references.citation: AIDS. 2005 Jun 10;19(9):943-7
references.pmid: 15905675
references.citation: J Med Chem. 2008 Oct 23;51(20):6599-603
references.pmid: 18808097
references.citation: Lancet. 2007 Jul 7;370(9581):3-5
references.pmid: 17617250
references.citation: AIDS. 2000 Jun 16;14(9):1203-10
references.pmid: 10894285
references.citation: J Med Chem. 2005 Mar 24;48(6):1813-22
references.pmid: 15771427
references.citation: AIDS Res Hum Retroviruses. 2008 Oct;24(10):1275-80
references.pmid: 18844462
references.citation: J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Mar 1;20(3):290-4
references.pmid: 10077179
references.citation: J Virol. 2004 Nov;78(21):12012-21
references.pmid: 15479840
references.citation: HIV Clin Trials. 2007 Jul-Aug;8(4):213-20
references.pmid: 17720661
references.citation: N Engl J Med. 2008 Jul 24;359(4):355-65
references.pmid: 18650513
references.citation: Lancet. 2007 Jul 7;370(9581):29-38
references.pmid: 17617270
references.citation: AIDS Res Hum Retroviruses. 2009 Apr;25(4):457-61
references.pmid: 19320601
references.citation: Ther Clin Risk Manag. 2008 Aug;4(4):759-66
references.pmid: 19209258
references.citation: AIDS. 1999 Oct 1;13(14):1933-42
references.pmid: 10513653
references.citation: AIDS. 2008 Jan 2;22(1):165-7
references.pmid: 18090413
references.citation: AIDS. 2008 Sep 12;22(14):1809-13
references.pmid: 18690163
references.citation: J Antimicrob Chemother. 2009 Mar;63(3):585-92
references.pmid: 19147519
references.citation: AIDS Rev. 2008 Jul-Sep;10(3):131-42
references.pmid: 18820715
references.citation: Top HIV Med. 2008 Oct-Nov;16(4):110-6
references.pmid: 18838744
references.citation: N Engl J Med. 2008 Jul 24;359(4):339-54
references.pmid: 18650512
references.citation: Antivir Ther. 2008;13(4):563-9
references.pmid: 18672535
references.citation: J Acquir Immune Defic Syndr. 2008 Oct 1;49(2):179-82
references.pmid: 18769351
references.citation: AIDS. 2007 Feb 19;21(4):395-402
references.pmid: 17301557
references.citation: J Mol Biol. 2008 Aug 1;381(1):102-15
references.pmid: 18597780
references.citation: J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):563-4
references.pmid: 19202459
references.citation: Clin Pharmacokinet. 2007;46(9):739-56
references.pmid: 17713972
references.citation: Top HIV Med. 2008 Dec;16(5):138-45
references.pmid: 19106428